Browsing eNauka
Browsing by Project Hoffmann-LaRoche
Showing results 1 to 20 of 29
next >
| Issue Date | Title | Author(s) | Type | Мp-cat. |
|---|---|---|---|---|
| 2021 | Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB plus ) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C | Dziadziuszko, R; ...; Andric, Zoran G   ; ...; (broj, koautora 20) | Conference Paper | Mp. category will be shown later |
| 2022 | Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial | Peters, Solange; ...; Andric, Zoran G ; ...; (broj, koautora 26) | Article | 21a+M21a+ |
| 2019 | Blood pressure distribution and control in coronary patients from 24 European countries in the European Society of Cardiology EURoObservational Research Programme European survey of cardiovascular disease prevention and diabetes. EUROASPIRE IV Registry | Cifkova, Renata; Lanska, Vera; Bruthans, Jan; Mayer, Otto Jr; Kotseva, Kornelia; Wood, David; Lovic, Dragan B ; De, Sutter Johan; Reiner, Zeljko; Fras, Zlatko;
Deckers, Jaap; Gotcheva, Nina; Georgiev, Borislav; De, Bacquer Dirk;
| Article | 21aM21a |
| 2023 | Cerebrospinal fluid and MRI analyses of fenebrutinib treatment in multiple sclerosis reveal brain penetration and early reduction of new lesion activity: results from the phase II FENopta study | Bar-Or, Amit; Dufek, Michal; Budinčević, Hrvoje; Drulović, Jelena S. ; Habek, Mario; Hua, Le; Weber, Martin; Thomas, Piia; Napieralski, Julie; Clayton, David;
Kuruvilla, Denison; Qi, Qi; Xu, Yan; Goodyear, Alexandra; Oh, Jiwon;
| Conference Paper | Mp. category will be shown later |
| 2015 | Cerebrovascular events in inflammatory bowel disease patients treated with anti-tumour necrosis factor alpha agents | Karmiris, Konstantinos; ...; Tarabar, Dino K; ...; (broj, koautora 20) | Article | 21aM21a |
| 2020 | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 21) | Conference Paper | Mp. category will be shown later |
| 2019 | Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study | Herbst, Roy S; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Conference Paper | Mp. category will be shown later |
| 2017 | Computed tomography versus invasive coronary angiography: design and methods of the pragmatic randomised multicentre DISCHARGE trial | Napp, Adriane E.; Haase, Robert; Laule, Michael; Schuetz, Georg M.; Rief, Matthias; Dreger, Henryk; Feuchtner, Gudrun; Friedrich, Guy; Spacek, Miloslav; Suchanek, Vojtech;
Kofoed, Klaus Fuglsang; Engstroem, Thomas; Schroeder, Stephen; Drosch, Tanja; Gutberlet, Matthias; Woinke, Michael; Maurovich-Horvat, Pal; Merkely, Bela; Donnelly, Patrick; Ball, Peter; Dodd, Jonathan D.; Quinn, Martin; Saba, Luca; Porcu, Maurizio; Francone, Marco; Mancone, Massimo; Erglis, Andrejs; Zvaigzne, Ligita; Jankauskas, Antanas; Sakalyte, Gintare; Haran, Tomasz; Ilnicka-Suckiel, Malgorzata; Bettencourt, Nuno; Gama-Ribeiro, Vasco; Condrea, Sebastian; Benedek, Imre; Adjic, Nada Cemerlic; Adjic, Oto; Rodriguez-Palomares, Jose; del Blanco, Bruno Garcia; Roditi, Giles; Berry, Colin; Davis, Gershan; Thwaite, Erica; Knuuti, Juhani; Pietila, Mikko; Kepka, Cezary; Kruk, Mariusz; Vidakovic, Radosav; Neskovic, Aleksandar N.; Diez, Ignacio; Lecumberri, Inigo; Geleijns, Jacob; Kubiak, Christine; Strenge-Hesse, Anke; Do, The-Hoang; Fromel, Felix; Gutierrez-Ibarluzea, Inaki; Benguria-Arrate, Gaizka; Keiding, Hans; Katzer, Christoph; Mueller-Nordhorn, Jacqueline; Rieckmann, Nina; Walther, Mario; Schlattmann, Peter; Dewey, Marc; DISCHARGE Trial Grp;
| Article | 21aM21a |
| 2023 | Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial | Livingstone, E; Gogas c , H.; Kandolf-Sekulović, Lidija O.; ...; Mijušković, Željko P. ; ...; (broj, koautora 24) | Article | 21aM21a |
| 2025 | Early switch from run-in with targeted to immunotherapy in advanced BRAFV600-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial | Livingstone, E; ...; Kandolf, Lidija O; ...; (broj, koautora 25) | Article | 21aM21a |
| 2024 | Early switch from targeted to immunotherapy in advanced BRAFV600-positive melanoma: Long-term OS and final PFS results of the randomized phase II ImmunoCobiVem trial | Schadendorf, Dirk; ...; Kandolf-Sekulovic, Lidija O; ...; Mijusković, Željko P. ; ...; (broj, koautora 20) | Conference Paper | Mp. category will be shown later |
| 2022 | Efficacy and safety of sequencing with vemurafenib (V) plus cobimetinib (C) followed by atezolizumab (Atezo) in patients (pts) with advanced BRAF(V600)-positive melanoma: Interim analysis of the ImmunoCobiVem study. | Schadendorf, Dirk; ...; Kandolf-Sekulovic, Lidija O; ...; Mijuskovic, Željko P ; ...; (broj, koautora 20) | Conference Paper | Mp. category will be shown later |
| 2017 | Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial | Davies, Andrew; Merli, Francesco; Mihaljevic, Biljana S ; Mercadal, Santiago; Siritanaratkul, Noppadol; Solal-Celigny, Philippe; Boehnke, Axel; Berge, Claude; Genevray, Magali; Zharkov, Artem;
Dixon, Mark; Brewster, Michael; Barrett, Martin; MacDonald, David;
| Article | 21a+M21a+ |
| 2023 | Five-Year Survival in Patients with ES-SCLC Treated with Atezolizumab in IMpower133: Imbrella a Extension Study Results | Liu, SV; ...; Andric, Zoran G ; ...; (broj, koautora 24) | Conference Paper | Mp. category will be shown later |
| 2024 | Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study | Reck, Martin; ...; Andric, Zoran G ; ...; (broj, koautora 24) | Article | 21M21 |
| 2025 | Global guideline for the diagnosis and management of candidiasis: an initiative of the ECMM in cooperation with ISHAM and ASM | Cornely, Oliver A.; ...; Barać, Aleksandra M. ; ...; (broj koautora 105) | Article | 21a+M21a+ |
| 2019 | IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1-selected NSCLC | Spigel, D; ...; Andric, Zoran G ; ...; (broj, koautora 20) | Conference Paper | Mp. category will be shown later |
| 2014 | Multiple sclerosis registries in Europe - results of a systematic survey | Flachenecker, Peter; ...; Sutovic, Dragana; ...; (broj, koautora 34) | Article | 21aM21a |
| 2020 | Neuraminidase Inhibitors and Hospital Length of Stay: A Meta-analysis of Individual Participant Data to Determine Treatment Effectiveness Among Patients Hospitalized With Nonfatal 2009 Pandemic Influenza A(H1N1) Virus Infection | Venkatesan, Sudhir; ...; Mikic, Dragan S; ...; (broj, koautora 70) | Article | 21aM21a |
| 2021 | Original Research Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study | O'Shaughnessy, Joyce; ...; Cvetanovic, Ana S; ...; Stamatovic, Ljiljana | Article | 21aM21a |